Digital health funding slowed in 2019

Global venture capital funding in digital health dropped 6% in 2019, with 615 deals nabbing $8.9 billion in capital, according to a new report from Mercom Capital Group.

By comparison, there were 698 deals in 2018 totaling $9.5 billion. Digital health companies in 2019 also snagged deals outside of venture capital––total corporate funding, including VC, debt and public market financing, hit $10.1 billion. M&A transactions were also down compared to 2018, dropping 24%. During the year, 169 M&A transactions occurred, compared to 223 in 2018. In addition, there were 19 companies that participated in multiple transaction in 2019.

Over the past decade, digital health companies have received $44 billion in VC funding, over 4,500 deals, as well as nearly $14 billion in debt and public market financing. That brings the total cumulative investments in the space to $58 billion. During the year, the average funding deal size was $14.4 million, up from an average of $13.6 million in 2018.

"It looks like venture funding into digital health may have peaked. Investors became a lot more careful last year after several tech companies were found to be overvalued," Raj Prabhu, CEO and Co-Founder of Mercom Capital Group, told Health Exec. "Weak post IPO performance of tech/digital health companies last year has also contributed to the cautious approach to investing, resulting in a slight decline in funding levels."

Telemedicine brought in the most investments in 2019 for the sector, with $1.8 billion, followed by data analytics ($1.6 billion) mhealth apps ($1.2 billion), clinical decision support ($748 million), mobile wireless technology ($556 million) and booking ($537 million).

After three consecutive years of growth, venture deals and dollars for digital health companies declined in 2019,” Raj Prabhu, CEO of Mercom Capital Group, said in a statement. “After a long dry spell, there were four U.S. IPOs, but their performance so far has been underwhelming. M&A activity also declined in 2019. The big winners were telemedicine companies, with a 55% percent increase in funding YoY while digital health products that were powered by AI, brought in over $2 billion.”

Consumer-centric companies brought in more investments compared to practice-centric companies during the year––$5.3 billion in 354 deals and $3.6 billion in 261 deals, respectively. The majority of deals were also conducted in the U.S.––426 deals amassed $5.9 billion in funding.

Here are some of the top transactions in 2019:

  1. Dassault Systemes’ $5.8 billion acquisition of Medidata
  2. A majority stake acquisition in Waystar for $2.7 billion but The EQT VIII Fund and Canada Pension Plan Investment
  3. Google’s $2.1 billion acquisition of Fitbit
  4. Golden Gate Capital’s $1.2 billion majority stake in Ensemble Health Partners
  5. Agfa-Gevaert Group’s $.107 billion acquisition of Dedalus Holding
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.